S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
IRD · Opus Genetics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$4.12
+0.10
(+2.49%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$4.12
$4.01
$4.21
52-WEEK RANGE
$4.12
$1.70
$7.07
What's happening
- IRD is up 2.49% today, trading at $4.12. — Live quote
- Volume today (199,620) is well below its 3-month average of 2,092,260. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.08 actual vs. $-0.16 estimated (+49.5%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 6
Buy 15
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (22 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
IRD
+99.50%
vs S&P 500
+86.73%
1-YEAR RETURN
IRD
+102.53%
vs S&P 500
+87.96%
6-MONTH RETURN
IRD
-30.26%
3-MONTH RETURN
IRD
+31.05%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.08
Est. $-0.16
BEAT +49.5%
2026-04-26 (Q1 2026)
$-0.75
Est. $-0.14
MISS -421.2%
2026-01-26 (Q4 2025)
$-0.29
Est. $-0.12
MISS -146.8%
2025-10-26 (Q3 2025)
$-0.25
Est. $-0.13
MISS -90.4%
Valuation Measures & Ratios
Enterprise Value4$289.7M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)34.74
Price / Book79.03
EV4 / Revenue29.40
EV4 / EBITDA9.96
Profit Margin-1091.82%
Operating Margin-513.47%
Return on Equity (ROE8)-316.35%
Return on Assets (ROA9)-174.89%
Avg Volume (3M)2,092,260
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $237.7M | $397.6M | $115.5M | $58.0M | $33.1M |
| P/E | -2.41 | -4.03 | -2.85 | -1.88 | -1.08 |
| Price/Sales | 26.79 | 31.84 | 8.14 | 4.74 | 2.99 |
| Price/Book | -18.31 | -8.67 | 19.36 | 3.32 | 6.52 |
| EV/Revenue | 20.76 | 27.04 | 5.97 | 2.09 | -0.79 |
| ROE | 758.56% | 215.12% | -680.31% | -176.87% | -603.02% |
| ROA | -105.96% | -147.64% | -112.38% | -79.93% | -63.51% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short13,013,222
Change from Prior Settlement+3.45%
% of Float—
Days to Cover (Short Ratio)6.05
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +102.5%. Finnhub market metrics ↗
- Latest SEC filing is Form 8-K, filed 2026-10-21; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -73.8% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -1091.8%. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on IRD
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $755.0K | $2.2M | $3.1M | $2.9M | $4.4M | $3.9M | $1.1M | $1.7M |
| Operating income | -$16.5M | -$14.4M | -$8.3M | -$8.9M | -$9.9M | -$8.0M | -$8.3M | -$7.7M |
| Net income | -$8.1M | -$65.5M | -$17.5M | -$7.4M | -$8.2M | -$7.5M | -$7.8M | -$7.1M |
| EPS (diluted) | $-0.14 | $-0.75 | $-0.25 | $-0.12 | $-0.24 | $-0.29 | $-0.30 | $-0.29 |
| EPS (basic) | $-0.08 | $-0.75 | $-0.25 | $-0.12 | $-0.24 | $-0.29 | $-0.30 | $-0.29 |
| Operating margin | -$2.2K | -$666 | -$270 | -$309 | -$227 | -$207 | -$749 | -$450 |
| Net margin | -$1.1K | -$3.0K | -$567 | -$257 | -$188 | -$195 | -$698 | -$415 |
Balance sheet
| Line item | Jun '26 | Apr '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $93.0M | — | $66.8M | $50.2M | $36.1M | $38.7M | $48.2M | $36.9M |
| Total liabilities | $106.0M | — | $87.9M | $34.9M | $30.2M | $21.2M | $24.3M | $11.3M |
| Stockholders' equity | -$13.0M | — | -$45.8M | $15.3M | $6.0M | $17.5M | $5.1M | $6.7M |
| Total current assets | $92.7M | — | $66.6M | $50.0M | $35.9M | $38.4M | $47.9M | $36.6M |
| Total current liabilities | $7.6M | — | $9.3M | $7.8M | $29.1M | $20.2M | $24.3M | $11.3M |
| Cash & equivalents | $88.8M | — | $60.0M | $45.1M | $30.8M | $32.4M | $41.8M | $30.3M |
| Marketable securities (current) | — | — | — | $0 | $0 | $0 | $1.0K | $2.0K |
| Accounts receivable | $1.0M | — | $1.7M | $2.0M | $2.9M | $3.4M | $3.1M | $3.6M |
| Other current assets | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $172.0K | — | $186.0K | $199.0K | $212.0K | $226.0K | $239.0K | $252.0K |
| Accounts payable | $1.9M | — | $4.4M | $3.3M | $2.4M | $1.5M | $2.4M | $3.1M |
| Accrued liabilities | — | — | — | $4.5M | — | — | — | $8.1M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | $35.3M | $35.3M | — | — | — | — | — | — |
| Common stock & paid-in capital | $8.0K | — | $7.0K | $7.0K | $6.0K | $6.0K | $5.0K | $3.0K |
| Retained earnings | -$262.2M | — | -$254.1M | -$188.6M | -$172.1M | -$154.6M | -$147.2M | -$139.0M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | — | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.9M | -$12.7M | -$9.8M | -$6.2M | -$10.3M | -$9.0M | -$7.4M | -$5.1M |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 | $0 | $1.2M | $0 |
| Financing cash flow | $40.9M | $27.6M | $24.1M | $4.5M | $906.0K | $20.5M | -$83.0K | $353.0K |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Share-based compensation | $1.4M | $1.5M | $774.0K | $816.0K | $896.0K | $913.0K | $795.0K | $776.0K |
| Change in accounts receivable | -$690.0K | -$264.0K | -$921.0K | -$483.0K | $319.0K | -$483.0K | $1.7M | $499.0K |
| Change in accounts payable | -$2.6M | $1.2M | $804.0K | $906.0K | -$985.0K | -$718.0K | $1.5M | $200.0K |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt issued | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $14.2M | $11.0M | $19.0M | $39.9M | $589.0K |
| Operating income | -$38.6M | -$62.1M | -$10.6M | $18.2M | -$22.7M |
| Net income | -$49.6M | -$57.5M | -$10.0M | $17.9M | -$56.7M |
| EPS (diluted) | $-0.80 | $-2.15 | $-0.46 | $0.87 | $-3.82 |
| EPS (basic) | $-0.80 | $-2.15 | $-0.46 | $0.90 | $-3.82 |
| Operating margin | -$272 | -$565 | -$55 | $46 | -$3.9K |
| Net margin | -$349 | -$523 | -$52 | $45 | -$9.6K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $50.2M | $36.9M | $53.9M | $49.0M | $26.1M |
| Total liabilities | $34.9M | $11.3M | $4.0M | $2.8M | $3.9M |
| Stockholders' equity | $15.3M | $6.7M | $49.9M | $46.2M | $22.2M |
| Total current assets | $50.0M | $36.6M | $53.9M | $49.0M | $26.1M |
| Total current liabilities | $7.8M | $11.3M | $4.0M | $2.8M | $3.9M |
| Cash & equivalents | $45.1M | $30.3M | $50.5M | $42.6M | $24.5M |
| Marketable securities (current) | $0 | $2.0K | $15.0K | $49.0K | $219.0K |
| Accounts receivable | $2.0M | $3.6M | $926.0K | $1.3M | $0 |
| Other current assets | — | — | $102.0K | $80.0K | $71.0K |
| Property, plant & equipment | $199.0K | $252.0K | $0 | $6.0K | $10.0K |
| Accounts payable | $3.3M | $3.1M | $2.2M | $1.1M | $1.6M |
| Accrued liabilities | $4.5M | $8.1M | $1.8M | $1.7M | $1.7M |
| Deferred revenue (current) | — | — | — | — | — |
| Short-term debt | — | — | — | $0 | $538.0K |
| Common stock & paid-in capital | $7.0K | $3.0K | $2.0K | $2.0K | $2.0K |
| Retained earnings | -$188.6M | -$139.0M | -$81.5M | -$71.5M | -$89.4M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$35.3M | -$25.6M | -$1.1M | $14.3M | -$19.4M |
| Investing cash flow | $0 | $1.2M | $0 | $0 | -$100.0K |
| Financing cash flow | $50.0M | $4.2M | $9.0M | $3.8M | $27.6M |
| Capital expenditures | — | — | — | — | — |
| Share-based compensation | $3.4M | $3.4M | $3.5M | $1.8M | $1.9M |
| Change in accounts receivable | -$1.6M | $2.6M | -$372.0K | $1.3M | $0 |
| Change in accounts payable | $7.0K | $220.0K | $1.1M | -$515.0K | $381.0K |
| Purchases of investments | — | — | — | — | — |
| Share repurchases | — | — | — | — | — |
| Debt issued | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding IRD as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers57.2%
Shares Outstanding95,483,280
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| Caligan Partners LP | 6,077,084 | $25.0M | 6.36% | +0.0% | 2026-08-14 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 6,029,775 | $24.8M | 6.32% | +0.0% | 2026-08-14 |
| BIOS Capital Management, LP | 3,683,429 | $15.1M | 3.86% | +0.0% | 2026-08-14 |
| BlackRock, Inc. | 3,116,487 | $12.8M | 3.26% | +2009.4% | 2026-08-07 |
| BALYASNY ASSET MANAGEMENT L.P. | 3,087,866 | $12.7M | 3.23% | +13.6% | 2026-08-13 |
| Nantahala Capital Management, LLC | 3,061,359 | $12.6M | 3.21% | +82.1% | 2026-08-14 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,958,683 | $12.2M | 3.10% | +20.8% | 2026-06-30 |
| Boxer Capital Management, LLC | 2,815,000 | $11.6M | 2.95% | +25.1% | 2026-08-14 |
| Trails Edge Capital Partners, LP | 2,743,658 | $11.3M | 2.87% | +448.7% | 2026-08-14 |
| MILLENNIUM MANAGEMENT LLC | 2,302,101 | $9.5M | 2.41% | -12.5% | 2026-08-14 |
| GREAT POINT PARTNERS LLC | 1,970,187 | $8.1M | 2.06% | +507.4% | 2026-08-14 |
| MARSHALL WACE, LLP | 1,945,609 | $8.0M | 2.04% | -15.9% | 2026-08-13 |
| ADAR1 Capital Management, LLC | 1,783,781 | $7.3M | 1.87% | -3.5% | 2026-08-14 |
| Goldman Sachs Group Inc | 1,527,229 | $6.3M | 1.60% | +367.3% | 2026-08-14 |
| Woodline Partners LP | 1,434,713 | $5.9M | 1.50% | +6.0% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 1,367,712 | $5.6M | 1.43% | +154.1% | 2026-08-12 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1,189,515 | $4.9M | 1.25% | +0.0% | 2026-08-14 |
| Opaleye Management Inc. | 1,125,000 | $4.6M | 1.18% | +0.4% | 2026-08-14 |
| SummitTX Capital, L.P. | 1,007,351 | $4.1M | 1.06% | +0.0% | 2026-08-14 |
| State Street Corp | 790,136 | $3.2M | 0.83% | +295.2% | 2026-08-07 |
| Bleichroeder LP | 736,842 | $3.0M | 0.77% | +0.0% | 2026-08-13 |
| UBS Group AG | 683,895 | $2.8M | 0.72% | +165.4% | 2026-08-13 |
| CITADEL ADVISORS LLC | 665,662 | $2.7M | 0.70% | +450.6% | 2026-08-14 |
| Morgan Stanley | 464,900 | $1.9M | 0.49% | +1076.3% | 2026-08-11 |
| Northern Trust Corp | 442,154 | $1.8M | 0.46% | +368.3% | 2026-08-12 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-03-16 to 2026-09-30
Recent transactions
- Insiders have net sold 2,352,034 shares over the last 182 days, across 0 purchases and 13 sales.
- Most recent: Foundation Fighting Blindness Retinal Degeneration Fund (Director) — Open market sale of 556,000 shares on 2026-09-30.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)2,352,034 sh(13 txns)
Net Shares-2,352,034
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Foundation Fighting Blindness Retinal Degeneration Fund | Director | Open market sale | 2026-09-30 | 556,000 |
| Magrath George | Chief Executive Officer | Option exercise | 2026-09-09 | 392,157 |
| Gallagher Cam | Reporting person | Option exercise | 2026-09-08 | 784,314 |
| Gagnon Robert E. | Chief Financial Officer | Open market sale | 2026-09-03 | 28,000 |
| YERXA BENJAMIN R | President | Open market sale | 2026-07-23 | 7,429 |
| SCHACHLE JOSEPH K | Chief Operating Officer | Open market sale | 2026-07-23 | 4,644 |
| Zaremba Rabourn Amy | Head of Fin. Quality Assurance | Open market sale | 2026-04-23 | 1,641 |
| Jayagopal Ashwath | Chief Scientific & Dev. Ofc. | Open market sale | 2026-04-23 | 7,542 |
| Rodgers Richard J | Reporting person | Grant / award | 2026-04-20 | 24,367 |
| MANUSO JAMES S J | Reporting person | Grant / award | 2026-04-20 | 24,367 |
| Graves Adrienne L | Reporting person | Grant / award | 2026-04-20 | 24,367 |
| Benton Susan | Reporting person | Grant / award | 2026-04-20 | 24,367 |
| Bennett Jean | Reporting person | Grant / award | 2026-04-20 | 24,367 |
| Ainsworth Sean | Reporting person | Grant / award | 2026-04-20 | 24,367 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | Foundation Fighting Blindness Retinal Degeneration Fund | Director | Open market sale | 556,000 | $4.96 |
| 2026-09-09 | Magrath George | Chief Executive Officer | Option exercise | 392,157 | $1.15 |
| 2026-09-09 | Magrath George | Chief Executive Officer | Tax withholding | 75,541 | $5.97 |
| 2026-09-08 | Gallagher Cam | Reporting person | Option exercise | 784,314 | $1.15 |
| 2026-09-03 | Gagnon Robert E. | Chief Financial Officer | Open market sale | 28,000 | $4.54 |
| 2026-07-23 | YERXA BENJAMIN R | President | Open market sale | 7,429 | $2.97 |
| 2026-07-23 | SCHACHLE JOSEPH K | Chief Operating Officer | Open market sale | 4,644 | $2.94 |
| 2026-07-23 | Magrath George | Chief Executive Officer | Open market sale | 9,475 | $2.95 |
| 2026-07-23 | Gagnon Robert E. | Chief Financial Officer | Open market sale | 7,783 | $2.95 |
| 2026-05-18 | Foundation Fighting Blindness Retinal Degeneration Fund | Director | Open market sale | 1,700,000 | $4.35 |
| 2026-04-23 | YERXA BENJAMIN R | President | Open market sale | 7,470 | $5.24 |
| 2026-04-23 | SCHACHLE JOSEPH K | Chief Operating Officer | Open market sale | 4,697 | $5.22 |
| 2026-04-23 | Zaremba Rabourn Amy | Head of Fin. Quality Assurance | Open market sale | 1,641 | $5.20 |
| 2026-04-23 | Magrath George | Chief Executive Officer | Open market sale | 9,511 | $5.22 |
| 2026-04-23 | Jayagopal Ashwath | Chief Scientific & Dev. Ofc. | Open market sale | 7,542 | $5.19 |
| 2026-04-23 | Gagnon Robert E. | Chief Financial Officer | Open market sale | 7,842 | $5.18 |
| 2026-04-20 | Rodgers Richard J | Reporting person | Grant / award | 24,367 | $0.00 |
| 2026-04-20 | MANUSO JAMES S J | Reporting person | Grant / award | 24,367 | $0.00 |
| 2026-04-20 | Graves Adrienne L | Reporting person | Grant / award | 24,367 | $0.00 |
| 2026-04-20 | Gallagher Cam | Reporting person | Grant / award | 24,367 | $0.00 |
| 2026-04-20 | Benton Susan | Reporting person | Grant / award | 24,367 | $0.00 |
| 2026-04-20 | Bennett Jean | Reporting person | Grant / award | 24,367 | $0.00 |
| 2026-04-20 | Ainsworth Sean | Reporting person | Grant / award | 24,367 | $0.00 |
| 2026-03-16 | SCHACHLE JOSEPH K | Chief Operating Officer | Open market sale | 3,719 | $5.25 |
| 2026-03-16 | Zaremba Rabourn Amy | Head of Fin. Quality Assurance | Open market sale | 2,816 | $5.25 |
| 2026-03-16 | Magrath George | Chief Executive Officer | Open market sale | 24,438 | $5.21 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 02:08 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-21 | 8-K | 2026-10-19 | View on SEC.gov → |
| 2026-10-15 | 8-K | 2026-10-14 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-09-11 | 4 | 2026-09-09 | View on SEC.gov → |
| 2026-09-11 | 8-K | 2026-09-11 | View on SEC.gov → |
| 2026-09-09 | 8-K | 2026-09-09 | View on SEC.gov → |
| 2026-09-08 | 4 | 2026-09-08 | View on SEC.gov → |
| 2026-09-08 | 4 | 2026-09-03 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-07-27 | 4 | 2026-07-23 | View on SEC.gov → |
| 2026-07-27 | 4 | 2026-07-23 | View on SEC.gov → |
Recent news
Headlines about IRD (Opus Genetics, Inc.). Links open the publisher — we don’t host full articles.
-
Opus Genetics receives FDA clearance for RDH12-LCA gene therapy By Investing.com
Investing.com Nigeria · 2026-10-21 -
Sector Update: Healthcare Stocks Decline Wednesday Afternoon
Yahoo · 2026-10-21 -
Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness
Yahoo · 2026-10-21 -
FDA Clears Opus Genetics’ IND Application For Opgx-RDH12, Investigational Gene Therapy For Treatment Of RDH12-Associated Leber Congenital Amaurosis
Benzinga · 2026-10-21 -
Opus Genetics at Chardan’s 10th annual healthcare conference: pipeline gains
Investing.com Nigeria · 2026-10-20 -
Opus Genetics stock rating maintained at outperform by Citizens
Investing.com · 2026-10-19 -
Opus Genetics, Inc. (IRD) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-17 -
Opus Genetics (IRD) Gains FDA Approval for Ryzumvi Label Expansi
GuruFocus · 2026-10-16
No headlines in this category right now — try “All”.